Recent Update,GLP-1 promotes insulin or glucagon-independent glucose clearance

Glucagon-like peptide-1 (GLP-1), a crucial peptide hormone in human physiology, plays a significant role in regulating glucose metabolism and influencing satiety. This 30-amino acid hormone, also referred to as Glucagon-Like Peptide I human or GLP-1, is primarily produced in the intestinal epithelial endocrine L-cells through the differential processing of proglucagon. Its discovery and subsequent research have illuminated its multifaceted actions, leading to a deeper understanding of metabolic health and the development of therapeutic strategies.

The production of GLP-1 is intrinsically linked to food intake. Upon the ingestion of nutrients, L-cells in the intestine release GLP-1 into the bloodstream. This release triggers a cascade of beneficial effects. One of the most well-documented actions of GLP-1 is its potent glucose-dependent stimulatory effect on insulin secretion from pancreatic beta-cells. This means that GLP-1 enhances insulin release when blood glucose levels are high, and has minimal effect when glucose levels are normal or low, thereby minimizing the risk of hypoglycemia. Furthermore, GLP-1 acts to suppress glucagon secretion from pancreatic alpha-cells, further contributing to blood glucose control. Studies have also suggested that GLP-1 promotes insulin or glucagon-independent glucose clearance and/or suppression of glucose production, indicating a broader impact on glucose homeostasis.

Beyond its direct effects on glucose metabolism, Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. This effect is mediated through its actions on the brain, where it influences appetite regulation centers. This property has made GLP-1 and its analogs attractive targets for the management of obesity. Indeed, the first drug in the class of GLP-1 agonists was approved in 2005 to treat diabetes, and subsequent research demonstrated their efficacy in treating obesity, earning them the moniker "wonder drugs of the 21st century."

The GLP-1 molecule itself exists in various forms, with the 7-36 amide form being the predominant circulating active form in humans. While in humans, almost all (>80%) secreted GLP-1 is amidated, a considerable part remains GLP-1 (7-37) in other species. The Glucagon-like peptide-1 (GLP-1) receptors are key to mediating these effects. These receptors are members of the glucagon receptor family and are found in various tissues, including the pancreas, stomach, and brain. The gene responsible for encoding the Glucagon-like peptide 1 receptor in humans is GLP1R, which is present on chromosome 6.

Research into Glucagon-like peptide-1 has also explored its potential therapeutic applications beyond diabetes and obesity. Some results suggest a novel role for Glucagon-Like Peptide I (7-36)-NH2 as a physiological inhibitor of gastric acid secretion in humans. This could have implications for managing conditions related to excessive stomach acid. Moreover, the potential for GLP-1 to be a novel therapeutic strategy for non-insulin-dependent (type 2) diabetes mellitus and associated neuropathy is an active area of investigation.

The scientific community has extensively studied Glucagon-like peptide-1. Landmark research, such as that by JJ Holst and DJ Drucker, has been pivotal in elucidating its physiological roles and therapeutic potential. The peptide is derived from the transcription product of the proglucagon gene, and its precise structure, like Glucagon Like Peptide-1, containing 30 amino acids and a molecular mass of approximately 3297.7 Daltons, has been well-characterized. Various forms, such as Glucagon-Like Peptide (GLP) I (7-36), amide, human, and Glucagon-Like Peptide I Amide Fragment 7-36 human, have been synthesized and utilized in research to study their specific activities and receptor interactions. The ability to measure levels or activity of GLP-1 is crucial for both research and clinical monitoring.

In summary, glucagon-like peptide-1 human is a vital incretin hormone that controls the metabolism of glucose by modulating insulin and glucagon secretion. Its influence extends to appetite regulation, promoting satiety and impacting energy intake. The ongoing research and development of GLP-1-based therapies highlight its significance in addressing metabolic disorders and improving human health. The intricate mechanisms by which this peptide operates continue to be a focus of scientific inquiry, promising further advancements in our understanding and treatment of related conditions.